|
|
| | HDAC6-IN-1 Basic information |
| Product Name: | HDAC6-IN-1 | | Synonyms: | HDAC6-IN-1;SKLB-23bb;Butanamide, N-hydroxy-4-[2-methoxy-5-[methyl(2-methyl-4-quinazolinyl)amino]phenoxy]-;SKLB 23bb,Histone deacetylases,Inhibitor,HDAC,inhibit,SKLB23bb,SKLB-23bb;N-Hydroxy-4-(2-methoxy-5-(methyl(2-methylquinazolin-4-yl)amino)phenoxy)butanamide | | CAS: | 1815580-06-3 | | MF: | C21H24N4O4 | | MW: | 396.44 | | EINECS: | | | Product Categories: | | | Mol File: | 1815580-06-3.mol |  |
| | HDAC6-IN-1 Chemical Properties |
| density | 1.271±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: Soluble | | form | A solid | | pka | 9.32±0.20(Predicted) |
| | HDAC6-IN-1 Usage And Synthesis |
| Uses | SKLB-23bb is an orally bioavailable and selective HDAC6 inhibitor with IC50 of less than 100 nM in most cell lines tested; it can be used to disrupt microtubule activity. | | in vitro | SKLB-23bb has toxic effects at low submolar levels in a range of solid and hematological tumor cell lines. Unlike reported selective HDAC6 inhibition, SKLB-23bb is more potent against solid tumors. SKLB-23bb selectively inhibits intracellular HDAC6, but its antitumor activity is independent of HDAC6. It can bind to the colchicine site of β-tubulin and is a microtubule polymerization inhibitor. SKLB-23bb also can arrest tumor cells in the G2-M phase and induce apoptosis. | | in vivo | In a solid tumor model, oral administration of SKLB-23bb can effectively inhibit tumor growth. It has favorable pharmacokinetic properties and is orally active. | | target | | Target | Value | HDAC6
(Cell-based assay) | <100 nM |
|
| | HDAC6-IN-1 Preparation Products And Raw materials |
|